51135-70-7

Basic information

• Product Name: 5-METHYL-PYRAZOLO[1,5-A]PYRIDINE-3-CARBOXYLIC ACID ETHYL ESTER
• Synonyms: 5-METHYL-PYRAZOLO[1,5-A]PYRIDINE-3-CARBOXYLIC ACID ETHYL ESTER;ETHYL 5-METHYLPYRAZOLO[1,5-A]PYRIDINE-3-CARBOXYLATE
• CAS NO: 51135-70-7
• Molecular Formula: C₁₁H₁₂N₂O₂
• Molecular Weight: 204.23
• Mol File: 51135-70-7.mol
• Article Data: 10

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 5-METHYL-PYRAZOLO[1,5-A]PYRIDINE-3-CARBOXYLIC ACID ETHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 5-METHYL-PYRAZOLO[1,5-A]PYRIDINE-3-CARBOXYLIC ACID ETHYL ESTER(51135-70-7)
• EPA Substance Registry System: 5-METHYL-PYRAZOLO[1,5-A]PYRIDINE-3-CARBOXYLIC ACID ETHYL ESTER(51135-70-7)

Safety Data

• Hazardous Substances Data: 51135-70-7(Hazardous Substances Data)

Usage

General Description

5-Methyl-pyrazolo[1,5-a]pyridine-3-carboxylic acid ethyl ester, also known as XK-469, is a pyrazolo[1,5-a]pyridine derivative that is commonly used in the field of medicinal chemistry. It is a potent and selective inhibitor of cyclin-dependent kinase 1 (CDK1) and cyclin-dependent kinase 2 (CDK2), making it a promising candidate for the development of anti-cancer drugs. XK-469 has shown potential in inhibiting the proliferation of cancer cells and inducing cell cycle arrest, making it a valuable compound for the treatment of various types of cancer. Its unique chemical structure and targeted mechanism of action make it a valuable tool for the study and development of novel cancer therapeutics.

Upstream product

• 13061-96-6 dihydroxy-methyl-borane 
• 885276-93-7 ethyl 5-bromopyrazolo[1,5-a]pyridine-3-carboxylate 
• 108-89-4 picoline 
• 38202-27-6 ethyl O-(2-mesitylenesulfonyl)acetohydroxamate 
• 105-37-3 Ethyl propionate 
• 623-47-2 propynoic acid ethyl ester 
• 51135-56-9 1-amino-4-methylpyridin-1-ium 2,4,6-trimethylbenzene sulfonate 

Downstream Products

• 143803-80-9 5-methylpyrazolo[1,5-a]pyridine-3-carboxylic acid 
• 1101118-06-2 N,2-dimethyl-N'-((5-methylpyrazolo[1,5-a]pyridin-3-yl)-methylene)-5-nitrobenzenesulfonohydrazide 

Relevant articles and documents

Design, synthesis and biological evaluation of ring-fused pyrazoloamino pyridine/pyrimidine derivatives as potential FAK inhibitors

We report herein the synthesis of novel ring-fused pyrazoloamino pyridine/pyrimidine derivatives as potential FAK inhibitors and the evaluation of pharmaceutical activity against five cancer cell lines (MDA-MB-231, BXPC-3, NCI-H1975, DU145 and 786O). Generally, the majority of compounds displayed strong anti-FAK enzymatic potencies (IC50 1 nM) and could effectively inhibit several class of cancer cell lines within the concentration of 3 μM in comparison with GSK2256098 as a reference. Among them, compound 4o is considered to be the most effective due to high sensitivity in antiproliferation. In culture, 4o could not only inhibit FAK Y397 phosphorylation in MDA-MB-231 cell line, but also trigger apoptosis in a dose-dependent manner. Furthermore, computational docking analysis also suggested that 4o and TAE-226 displayed the similar interaction with FAK kinase domain.

Focal adhesion kinase inhibitor and use

The invention belongs to the field of medicines, relates to a focal adhesion kinase inhibitor and use, in particular relates to a novel focal adhesion kinase inhibitor compound, or stereoisomers, geometric isomers, tautomers, oxynitrides, hydrates, solvates, metabolites, pharmaceutically acceptable salts or prodrugs thereof, further relates to the use of the compound and pharmaceutical compositions as medicines, in particular the use of the compound and pharmaceutical compositions in manufacture of medicines for treatment or prevention of cancer, pulmonary hypertension, and pathological angiogenesis-related diseases.

2-(PYRAZOLOPYRIDIN-3-YL)PYRIMIDINE DERIVATIVES AS JAK INHIBITORS

New 2-(pyrazolopyridin-3-yl)pyrimidine derivatives are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Janus Kinases (JAK).